Cincinnati, OH Clinical Trials Report — June 2026

For Cincinnati residents considering participation in clinical research, June 2026 presents both urgent opportunities and promising new avenues to contribute to medical science. Across Cincinnati, OH, a significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals.

A total of 62 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Duchenne muscular dystrophy (3 trials)
• Epilepsy (3 trials)
• Advanced solid tumor (2 trials)
• Ischemic stroke (2 trials)
• Anxiety (1 trial)
• Aortic insufficiency (1 trial)
• Adenine phosphoribosyltransferase deficiency (1 trial)
• Attention-deficit/hyperactivity disorder (1 trial)
• AKI (1 trial)
• Bacterial infection (1 trial)

New Research Opportunities Emerge in Cincinnati

This month, Cincinnati saw the opening of 17 new clinical trials, an increase from the 10 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in Cincinnati, OH, to 1,062 across 346 research facilities, underscoring the city's robust research landscape.

June brings several high-profile new trials to Cincinnati, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Pfizer is initiating a notable Phase 3 study, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to learn about the safety and effectiveness of a new pneumococcal vaccine in infants against infections like pneumonia and meningitis.
• Another Phase 3 study from Pfizer is NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents." This trial targets 1,200 participants to evaluate the safety and immune response of a new pneumococcal vaccine in older children and adolescents.
• AstraZeneca is sponsoring NCT07662135, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This study seeks 900 participants to evaluate a new treatment for type 2 diabetes with impaired kidney function.
• Convergent Genomics, Inc. is leading NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This observational study aims for 2,500 participants to collect urine and tumor samples for a new bladder cancer detection platform.
• AngioInsight is sponsoring NCT07676097, "Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study." This observational study involves 620 participants to establish the diagnostic performance of the AngioAI+ System for assessing coronary artery disease.
• The Children's Hospital Medical Center, Cincinnati is sponsoring NCT07649213, "Congenital Hemolytic and Dyserythropoietic Anemias." This research aims for 400 participants to better understand how red blood cells are formed incorrectly or break down easily in certain conditions.

New trials this month are exploring a range of conditions, with the most frequent being pneumococcal disease (2 trials) and narcolepsy (2 trials). Other conditions include bladder cancer (1 trial), cataplexy (1 trial), dyskeratosis congenita (1 trial), EDS (1 trial), epilepsy (1 trial), epilepsy in youth (1 trial), fatigue (1 trial), and hematuria (1 trial). Drug trials account for the largest share of new studies, with 7 new drug trials, followed by 4 "OTHER" type trials and 3 biological studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 3 of the 17 new trials launched this month are actively seeking healthy volunteers. Across Cincinnati, a total of 89 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Cincinnati's Leading Research Facilities

Cincinnati is home to some of the region's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Cincinnati Children's Hospital Medical Center (257 trials)
• University of Cincinnati (103 trials)
• University of Cincinnati Medical Center (62 trials)
• University of Cincinnati Cancer Center-UC Medical Center (56 trials)
• Good Samaritan Hospital - Cincinnati (47 trials)
• Bethesda North Hospital (46 trials)
• TriHealth Cancer Institute-Westside (39 trials)
• TriHealth Cancer Institute-Anderson (39 trials)
• Cincinnati Children's Hospital (37 trials)
• The Christ Hospital (37 trials)
• Oncology Hematology Care Inc-Kenwood (30 trials)

These institutions offer a broad spectrum of research, from pediatric specialties at Cincinnati Children's Hospital Medical Center to diverse medical fields at the University of Cincinnati and its affiliated medical centers, as well as comprehensive cancer care at various TriHealth and UC facilities.

Broadening Your Search: Nearby Options in Ohio

While Cincinnati offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Ohio. Cities with active trials include Columbus (19 trials), Cleveland (12 trials), Dayton (6 trials), South Euclid (2 trials), West Chester (2 trials), Milford (2 trials), North Royalton (1 trial), and Wadsworth (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 8 include children and 12 include older adults, ensuring that various age groups have ample opportunity to contribute to medical science. Industry sponsors are driving a significant portion of new research this month, with 9 new industry-sponsored trials, compared to 7 from other types of sponsors and 1 from a network. Notable sponsors for new trials include Children's Hospital Medical Center, Cincinnati (6 trials), AstraZeneca (2 trials), and Pfizer (2 trials).

As we move through June, Cincinnati's active research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.